A new hepatitis B virus e antigen-negative strain gene used as a reference sequence in an animal model.
PMID: 29339154
2018
Biochemical and biophysical research communications
Abstract: The main four point variants including A1762T, G1764A, G1896A, and G1899A were detected in the full-length genome.
Abstract: The strain will increase viral replication and infection for mutations A1762T and G1764A in the basal core promoter region, and mutations G1896A and G1899A in the pre-core region.
Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.
Abstract: RESULTS: Among the major mutant variants detected, double BCP mutations (A1762T/G1764A) (25.9%), Kozak sequences mutations (nt1809-1812) (51.7%) and the classical PC mutations such as A1814C/C1816T (15.4%), G1896A (25.2%) and G1862T (44.8%) were predominant mutant variants.
Discussion: As the result of BCP polymorphism, clinically important multiple mutations per a study subject; such as T1753V/A1762T/G1764A and A1762T/G1764A/C1766T (or
Molecular characterization of hepatitis B virus X gene in HIV-positive South Africans.
Introduction: By using the plasma samples from the members of the QBC, we found the A1762T/G1764A double mutation of the HBV basal core promoter (BCP) was frequently detected in HBV infected participants.
Introduction: However, the A1762T/G1764A double mutation alone was not sufficient to produce a statistically significant association with PLC.
Introduction: While A1762T/G1764A, C1653T, A799G, A987G, T1055A, pre-S deletion could be detected in the plasma long before P
Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.
Abstract: Baseline pcG1896A mutation was identified in 51 (59.3%) patients, who were more commonly HBeAg-negative (P < .001) and had basal core promotor A1762T/G1764A mutations (P < .001).
[Monitoring by high-sensitivity HBV DNA assay during treatment in chronic hepatitis B e antigen negative patients].
Abstract: For 49 cases of HBeAg-negative patients, HBV B, C, B and C were mixed before tenofovir dipivoxil treatment, and C1653T, A1762T and G1764A mutation sites were detected in patients with D genotype.
Clinical implication and viral mutation in basal core promoter/pre-core of hepatitis B virus C/D recombinant.
Abstract: Significantly higher levels of HBV DNA (6.7 ± 1.6 vs. 5.9 ± 1.5, p = 0.014), HBeAg (263.5 vs. 20.0, p = 0.013) and A1762T/G1764A double-mutations (81.0 vs. 61.8%, p = 0.018)
Abstract: The clonal frequencies of A1762T, G1764A, G1896A and A1846T were lower in patients with C/D than C2.
Association of characteristics of HBV quasispecies with hepatitis B surface antigen seroconversion after pegylated interferon-alpha-2a treatment in child patients.
Abstract: The baseline mutations A1762T/G1764A, C1913A, and T2003A/G or C2004T were correlated with non-response to therapy (P=0.025, P=0.036, P=0.032, respectively).
The Correlation Between Hepatitis B Virus Precore/Core Mutations and the Progression of Severe Liver Disease.
PMID: 30406036
2018
Frontiers in cellular and infection microbiology
Introduction: Similarly, the role of the precore mutation G1896A and the basal core promoter double mutation A1762T/G1764A in the progression of HBV-related liver diseases has been intensively studied (Kim et al.,).
[Risk factors analysis and a new risk scoring system predicting hepatocarcinogenesis for chronic genotype C HBV infected patients].
PMID: 30462954
2018
Zhonghua liu xing bing xue za zhi
Abstract: In genotype C HBV infected patients, male gender, aged 40 years and over, and four DNA mutations (T1674CG, A1762T/G1764A, A3120T, and A2962G) can increase the risk of HCC (P<0.05); interferon therapy can reduce the risk of HCC (P<0.05).
HBV mutation literature information.
PMID: 
2018
Biochemical and biophysical research communications
Browser Board
Co-occurred Entities
Filtrator
ViMRT